Abstract: Novel lactones of the formula ##STR1## wherein the dotted line indicates the optional presence of a second bond, A is a single bond or --CH.sub.2 --CH.sub.2 --, R is selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms and alkenyl and alkynyl of 2 to 4 carbon atoms, R.sub.6 is --OR.sub.A ', R.sub.A ' is selected from the group consisting of hydrogen, tetrahydropyranyl, alkyl of 1 to 3 carbon atoms and ##STR2## R.sub.A " is selected from the group consisting of alkyl of 1 to 3 carbon atoms optionally substituted with carboxyl and phenyl optionally substituted with a member of the group consisting of carboxyl, free hydroxyl, hydroxyl protected with an acyl of 2 to 4 carbon atoms and hydroxyl protected with an easily hydrolyzable group and R and R.sub.6 together form a keto group, R.sub.7 is --CH.sub.2).sub.m.sbsb.A --CH.sub.3, m.sub.A is 3,4,5 or 6 and R.sub.6 and R.sub.7 taken together form .dbd.CH--(CH.sub.2).sub.n.sbsb.A --CH.sub.3, n.sub.

Abstract: Novel .beta.-lactones of 2-hydroxy-cyclopentane-carboxylic acids of the formula ##STR1## wherein R.sub.1 is selected from the group consisting of hydrogen and methyl and R.sub.2 is selected from the group consisting of --CH.sub.2 --O--CH.sub.2 --CH.sub.3 and --X--Ar, X is selected from the group consisting of --O-- and --CH.sub.2 --, Ar is an optionally substituted member selected from the group consisting of thienyl, thiazolyl, phenyl and thiadiazolyl, the optional substituents being at least one member selected from the group consisting of halogen and --CF.sub.3 and thw wavy lines indicate that the groups may be in the .alpha., .beta. or .beta., .alpha.-positions or mixtures thereof having hypotensive activity and their preparation.

Abstract: Novel lactones of the formula ##STR1## wherein the dotted line indicates the optional presence of a second bond, A is a single bond or --CH.sub.2 --CH.sub.2 --, R is selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms and alkenyl and alkynyl of 2 to 4 carbon atoms, R.sub.6 is --OR'.sub.A, R'.sub.A is selected from the group consisting of hydrogen, tetrahydropyranyl, alkyl of 1 to 3 carbon atoms and ##STR2## R".sub.A is selected from the group consisting of alkyl of 1 to 3 carbon atoms optionally substituted with carboxyl and phenyl optionally substituted with a member of the group consisting of carboxyl, free hydroxyl, hydroxyl protected with an acyl of 2 to 4 carbon atoms and hydroxyl protected with an easily hydrolyzable group and R and R.sub.6 together form a keto group, R.sub.7 is --(CH.sub.2)m.sub.A --CH.sub.3, m.sub.A is 3,4,5 or 6 and R.sub.6 and R.sub.7 taken together form .dbd. CH--(CH.sub.2)n.sub. A --CH.sub.3 n.sub.

Abstract: Novel cyclopropanecarboxylic acids and esters of the formula ##STR1## wherein Z.sub.1 and Z.sub.2 are selected from the group consisting of hydrogen, alkyl, aralkyl, aryl, alkenyl non-conjugated with the cyclopropane ring, alkynyl non-conjugated with the cyclopropane ring, cycloalkyl, cycloalkenyl and heterocyclic; R is selected from the group consisting of OH and OR' in which R' is selected from the group consisting of lower alkyl which may be substituted, benzyl which may be substituted on the phenyl or methylene portion, N-methylene-dicarboximide, (5-benzyl-furyl-3) methyl, and a cyclopentene of the formula ##STR2## wherein R" is selected from the group consisting of alkyl, alkynyl, alkenyl, aryl, aralkyl, cycloalkyl, cycloalkenyl and heterocyclic; A is a bivalent alkyl radical selected from the group consisting of ##STR3## wherein R.sub.1 is selected from the group consisting of hydrogen and lower alkyl, R.sub.2 and R.sub.

Abstract: Novel 11-desoxy-prostaglandin F.sub.2 derivatives of the formula ##STR1## wherein R is selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms, an alkali metal, an equivalent of an alkaline earth metal, magnesium or organic amine base, R.sub.1 and R.sub.2 are individually seleced from the group consisting of hydrogen and methyl and X is selected from the group consisting of ##STR2## and a 5 to 6 membered heterocycle optionally substituted with at least one member of the group consisting of halogen, --CN and alkyl of 1 to 5 carbon atoms and X.sup.1 is a 6 member heterocycle with the wavy lines indicating that the hydroxy may be in either one of the two possible .alpha. and .beta. positions having hypotensive activity and process for their preparation.

Abstract: Novel cyclopentanol compounds of the formula ##STR1## wherein R is selected from the group consisting of ##STR2## R' is selected from the group consisting of hydrogen, alkyl of 1 to 12 carbon atoms and a non-toxic, pharmaceutically acceptable cation, R" is alkyl of 1 to 6 carbon atoms, R.sub.1 is selected from the group consisting of hydrogen and straight or branched chain, saturated and unsaturated alkyl of 1 to 4 carbon atoms and R.sub.2 is selected from the group consisting of hydrogen and tetrahydropyranyl, the wavy lines connecting R and --OH to the cyclopentane ring and --OR.sub.2 and R.sub.1 to the chain indicates that the substituents may be in either of the possible positions on the carbon atom to which they are attached and the dotted line indicates the optional presence of a double bond which possess analgesic, anti-inflammatory and smooth muscle relaxant activity and their preparation.

Abstract: Novel cyclopropanecarboxylic acids and esters of the formula ##STR1## wherein Z.sub.1 and Z.sub.2 are selected from the group consisting of hydrogen, alkyl, aralkyl, aryl, alkenyl non-conjugated with the cyclopropane ring, alkynyl non-conjugated with the cyclopropane ring, cycloalkyl, cycloalkenyl and heterocyclic; R is selected from the group consisting of OH and OR' in which R' is selected from the group consisting of lower alkyl which may be substituted, benzyl which may be substituted on the phenyl or methylene portion, N-methylene-dicarboximide, (5-benzyl-furyl-3) methyl, and a cyclopentene of the formula ##STR2## WHEREIN R" is selected from the group consisting of alkyl, alkynyl, alkenyl, aryl, aralkyl, cycloalkyl, cycloalkenyl and heterocyclic; A is a bivalent alkyl radical selected from the group consisting of ##STR3## WHEREIN R.sub.1 is selected from the group consisting of hydrogen and lower alkyl, R.sub.2 and R.sub.

Abstract: Novel cyclopentanones of the formula ##STR1## wherein AlK is alkyl of 1 to 4 carbon atoms, R is selected from the group of hydrogen and .alpha.-tetrahydropyranyl and the Ys are hydrogen or together represent a double bond with the proviso that when R is hydrogen, the Ys are hydrogen as well as products of the formula ##STR2## wherein AlK is alkyl of 1 to 4 carbon atoms and products of the formula ##STR3## wherein R and AlK have the above definitions which are useful intermediates in the production of prostaglandins.

Abstract: Novel cyclopentenecarboxylates of the formula ##STR1## wherein AlK is alkyl of 1 to 4 carbon atoms and R is selected from the group consisting of --CHO and --CH.sub.

Abstract: Novel cyclopentanoic acid derivatives of the formula ##STR1## wherein R is selected from the group consisting of ##STR2## and --CH.sub.2 OH, R' is selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms and a non toxic, pharmaceutically acceptable cation and R.sub.1 is selected from the group consisting of hydrogen, 2-tetrahydropyranyl, branched or straight chain, saturated or unsaturated alkyl of 1 to 4 carbon atoms and ##STR3## and R.sub.2 is selected from the group consisting of straight or branched chain alkyl of 1 to 12 carbon atoms and phenyl with the alkyl and phenyl being optionally substituted with --COOA wherein A is selected from the group consisting of hydrogen, alkali metal, ammonium ion, ion of an organic amine, alkyl and haloalkyl of 1 to 7 alkyl carbon atoms with the proviso that R.sub.1 is not hydrogen or 2-tetrahydropyranyl when R is a carboxylic group, and the OH and R groups on the ring and OR.sub.

Abstract: Novel prostanoic acid derivatives of the formula ##STR1## wherein R is hydrogen or alkyl having 1 to 4 carbon atoms, m is a whole number from 3, 4 or 5, n is a whole number from 2, 3 or 4, R' is either a linear or branched, saturated or unsaturated aliphatic hydrocarbon having 1 to 4 carbon atoms, or a saturated or mono unsaturated cyclohydrocarbon having 3 to 6 carbon atoms and A is either alkoxy having 1 to 4 carbon atoms or oxygen of a ketonic group, the dotted lines in the pentagonal ring are possible positions of a single double bond where, when A is a ketonic oxygen, the double bond is on the exterior of the ring and when A is alkoxy, the double bond is in one of the two interior positions of the ring, as well as the pharmaceutically compatible salts of mineral or organic bases when R is hydrogen in their .alpha.,.beta. or .beta.,.alpha. forms and mixtures thereof; as well as the process for their preparation, and the therapeutic compositions containing them.

Abstract: A novel process for the preparation of derivatives of prostanoic acids of the prostaglandin A.sub.2 (PGA.sub.2) group of the formula ##STR1## wherein R is selected from the group consisting of hydrogen and lower alkyl, n is a whole number of 2, 3 or 4 and m is a whole number of 3, 4 or 5 and to novel intermediates produced in the said process.

Abstract: Novel cyclopropanecarboxylic acids and esters of the formula ##STR1## wherein Z.sub.1 and Z.sub.2 are selected from the group consisting of hydrogen, alkyl, aralkyl, aryl, alkenyl non-conjugated with the cyclopropane ring, alkenyl non-conjugated with the cyclopropane ring, cycloalkyl, cycloalkenyl and heterocyclic; R is selected from the group consisting of OH and OR' in which R' is selected from the group consisting of lower alkyl which may be substituted, benzyl which may be substituted on the phenyl or methylene portion, N-methylene-dicarboximide, (5-benzyl-furyl-3) methyl, and a cyclopentene of the formula ##STR2## WHEREIN R" is selected from the group consisting of alkyl, alkynyl, alkenyl, aryl, aralkyl, cycloalkyl, cycloalkenyl and heterocyclic; A is a bivalent alkyl radical selected from the group consisting of ##STR3## WHEREIN R.sub.1 is selected from the group consisting of hydrogen and lower alkyl, R.sub.2 and R.sub.

Abstract: A novel process for the preparation of substituted trans-epoxy cis-alkenes of the formula ##EQU1## wherein Alk is straight or branched alkyl of 1 to 6 carbon atoms and m is 3,4 or 5 which are intermediates for prostaglandin compounds.

Abstract: Novel prostanoic acid derivatives of the formula ##STR1## wherein R is selected from the group consisting of hydrogen and alkyl of 1 to 7 carbon atoms, R.sub.1 is selected from the group consisting of hydrogen and carbalkoxy of 1 to 7 alkyl carbon atoms, R.sub.2 is selected from the group consisting of hydrogen, carboxy and carbalkoxy of 1 to 7 alkyl carbon atoms, R.sub.3 is selected from the group consisting of hydrogen and .alpha.-tetrahydropyranyl .Iadd.and at least one of R.sub.1, R.sub.2 and R.sub.3 is other than hydrogen.Iaddend., m is 3, 4 or 5 and n is 2, 3 or 4 with the proviso that when R.sub.1 is carbalkoxy, R is alkyl of 1 to 7 carbon atoms, R.sub.2 is hydrogen and R.sub.3 is .alpha.-tetrahydropyranyl; when R.sub.2 is carbalkoxy, R is alkyl of 1 to 7 carbon atoms, R.sub.1 is hydrogen and R.sub.3 is .alpha.-tetrahydropyranyl and when R.sub.2 is carboxy, R and R.sub.1 are hydrogen and R.sub.3 is .alpha.-tetrahydropyranyl, which possess the physiological activity of prostaglandins .[.